Tech notes

image of the tech note document

SomaScan® Assay v4.1

The SomaScan® Platform is a powerful tool with applications in scientific research and health and wellness. This technical note provides background on the platform itself, as well as performance metrics for the SomaScan® Assay v4.1.

Download Tech Note

image of the tech note document

Characterization of the binding specificity of SOMAmer® reagents used in the SomaScan® Assay

“Slow Off-rate Modified Aptamer” (SOMAmer) reagents are identified via the SELEX process against epitopes on a single target protein in buffer. While this shape recognition is highly specific, some proteins share structural and/or functional properties, and thus could be bound by a SOMAmer reagent originally selected against another protein. In order to test the specificity of SOMAmer reagents used in the SomaScan Assay for their respective initial target proteins, we perform a variety of characterization steps. These steps include: all affinity reagents (antibodies, traditional aptamers, etc.) are subject to specificity issues. Recognizing how critical the accuracy of the SomaScan Assay is for both research and clinical purposes, SomaLogic is committed to regular assessment of SOMAmer specificity, and to transparency in communicating the results of those ongoing efforts.

Download Tech Note

image of the tech note document

Pre-analytical variation assessment for more reliable results

In biomarker discovery, it is critical to assess any pre-analytical variation in order to avoid artificial bias in the intended measurements. Pre-analytical variation may arise from both avoidable and unavoidable factors, resulting in misleading data and incorrect conclusions.

Download Tech Note

image of the tech note document

Predicting Fibrotic NASH, or at-risk NASH, with the SomaScan® Assay

Non-alcoholic steatohepatitis (NASH) is a combination of liver inflammation, cell destruction, and accumulation of fat and scar tissue in the liver. NASH can progress to advanced liver fibrosis and Cirrhosis, leading to liver failure. The rapidly growing incidence of NASH worldwide is linked to the increase in type 2 Diabetes and obesity, and it has become the most common chronic liver disease.

Download Tech Note

image of the tech note document

SomaScan® Assay v4.0 and v4.1

The SomaScan Platform is a powerful tool with applications in scientific research and health and wellness.

This technical note provides background on the platform itself, as well as performance metrics for the SomaScan Assay v4.0 and v4.1.

Download Tech Note

image of the tech note document

SomaScan® Assay v4.1 signaling in mouse plasma

The SomaScan Assay v4.1 measures nearly 7,000 unique human proteins in a single sample.
This technical note describes a series of studies to demonstrate signaling of mouse plasma samples in the SomaScan Assay.

Download Tech Note

image of the tech note document

SomaScan® v4 data standardization and file specification technical note

Definition of processes used to remove assay and sample bias from SomaScan v4 data and file specification for SomaScan results.

Download Tech Note

image of the tech note document

SomaScan® v4.0 and v4.1 data standardization

Raw SomaScan Assay data may contain systematic biases from many sources, such as variation introduced by the readout, pipetting errors, inherent sample variation, or consumable reagent changes. Standardization is an important tool for removing nuisance variance.

Download Tech Note

image of the tech note document

Specificity elements of SOMAmer® reagents and the SomaScan® Assay

SOMAmer reagents bind to their target proteins in a highly specific manner with affinities comparable to and often exceeding those of antibodies. This technical note summarizes some of the existing evidence for the exquisite specificity of SOMAmer reagents.

Download Tech Note

image of the tech note document

The SomaScan® Assay: recommended sample handling and processing for core sample types

The following procedures are recommendations for the collection and preparation of samples for research use only assays on the SomaScan® Platform at SomaLogic. Other methods that prevent protein denaturation may be used, but please consult with your SomaLogic representative to discuss the details prior to implementation of an alternative collection protocol.  

For non-core sample types, see the Recommended Sample Handling and Processing for Non-Core Sample Types document.

Download Tech Note

image of the tech note document

The SomaScan® Assay v4.0 and v4.1 stability

The SomaScan® v4.0 and v4.1 Assays are run using 96 well plates; eleven wells are allocated for control samples used to control for batch effects and to estimate the accuracy, precision, and buffer background of the assay over time. Five pooled calibrator replicates, three pooled quality control (QC) replicates, and three buffer

Download Tech Note

image of the tech note document

Urine measurements on the SomaScan® v4.1 Assay

Urine is a non-invasive sample type with strong potential for biomarker discovery. We have developed sample processing and data standardization strategies to now utilize urine in the SomaScan Assay. Performance characteristics for urine in the SomaScan® Assay are described.

Download Tech Note